Treatment of Atopic Dermatitis Using a Full-Body Blue Light Device (AD-Blue): Protocol of a Randomized Controlled Trial
Irradiation with visible blue light (wavelength 400-495 nm) is a promising, effective, and safe new treatment option for chronic inflammatory skin diseases such as psoriasis and atopic dermatitis. We will perform a multicenter, placebo-controlled, double-blinded, 3-armed, prospective, randomized con...
Gespeichert in:
| Veröffentlicht in: | JMIR research protocols 2019-01, Vol.8 (1), p.e11911-e11911 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e11911 |
|---|---|
| container_issue | 1 |
| container_start_page | e11911 |
| container_title | JMIR research protocols |
| container_volume | 8 |
| creator | Kromer, Christian Nühnen, Viktoria P Pfützner, Wolfgang Pfeiffer, Sebastian Laubach, Hans-Joachim Boehncke, Wolf-Henning Liebmann, Joerg Born, Matthias Schön, Michael P Buhl, Timo |
| description | Irradiation with visible blue light (wavelength 400-495 nm) is a promising, effective, and safe new treatment option for chronic inflammatory skin diseases such as psoriasis and atopic dermatitis.
We will perform a multicenter, placebo-controlled, double-blinded, 3-armed, prospective, randomized controlled trial to investigate the efficacy and safety of full-body blue light devices (wavelengths: 415 nm and 450 nm) compared with that of placebo irradiation for the treatment of atopic dermatitis.
We are planning to enroll a total of 150 patients at the University hospitals in Göttingen (Germany), Marburg (Germany), and Geneva (Switzerland).
The trial was approved by the lead ethics committee of the medical faculty of the University of Göttingen (21/11/16). Further approvals were obtained from local and federal authorities (ethics committee Marburg, Cantonal Commission for Research Ethics Geneva, Suisse Medic, and Bundesinstitut für Arzneimittel und Medizinprodukte).
We will disseminate the results in a peer-reviewed journal.
ClinicalTrials.gov NCT03085303; https://clinicaltrials.gov/ct2/show/NCT03085303 (Archived by WebCite at http://www.webcitation.org/73ucqkkA1).
DERR1-10.2196/11911. |
| doi_str_mv | 10.2196/11911 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6329412</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2165657764</sourcerecordid><originalsourceid>FETCH-LOGICAL-c391t-4231637c186c1ab6a01d2b8c638c7c5eb43bc3e7663d58121ee51b4909010dfe3</originalsourceid><addsrcrecordid>eNpdkdFrFDEQxoMottT7FyQgQn1YzSS72Y0PwvVqVThQ5Pocstm5a0p2cybZSv3rzdlaqvMyw8yPj2_4CFkAe8tByXcACuAJOQbFVcXaunv6aD4ii5SuWamubRWXz8mRYJJz1qlj8nMT0eQRp0zDli5z2DtLzzGOJrvsEr1MbtpRQy9m76uzMNzSMz8jXbvdVS7cjbNIT5fn1WH75j39FkMONviDmKHfzTSE0f3Cga7ClGPwvoyb6Ix_QZ5tjU-4uO8n5PLi42b1uVp__fRltVxXVijIVc0FSNFa6KQF00vDYOB9Z6XobGsb7GvRW4GtlGJoOuCA2EBfK6YYsGGL4oR8uNPdz_2Igy2PRuP1PrrRxFsdjNP_XiZ3pXfhRkvBVQ28CJzeC8TwY8aU9eiSRe_NhGFOmoNsZNO2si7oq__Q6zDHqbynecM6KXmBCvX6jrIxpBRx-2AGmD6kqf-kWbiXj50_UH-zE78BXduXwg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2508662643</pqid></control><display><type>article</type><title>Treatment of Atopic Dermatitis Using a Full-Body Blue Light Device (AD-Blue): Protocol of a Randomized Controlled Trial</title><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Kromer, Christian ; Nühnen, Viktoria P ; Pfützner, Wolfgang ; Pfeiffer, Sebastian ; Laubach, Hans-Joachim ; Boehncke, Wolf-Henning ; Liebmann, Joerg ; Born, Matthias ; Schön, Michael P ; Buhl, Timo</creator><creatorcontrib>Kromer, Christian ; Nühnen, Viktoria P ; Pfützner, Wolfgang ; Pfeiffer, Sebastian ; Laubach, Hans-Joachim ; Boehncke, Wolf-Henning ; Liebmann, Joerg ; Born, Matthias ; Schön, Michael P ; Buhl, Timo</creatorcontrib><description>Irradiation with visible blue light (wavelength 400-495 nm) is a promising, effective, and safe new treatment option for chronic inflammatory skin diseases such as psoriasis and atopic dermatitis.
We will perform a multicenter, placebo-controlled, double-blinded, 3-armed, prospective, randomized controlled trial to investigate the efficacy and safety of full-body blue light devices (wavelengths: 415 nm and 450 nm) compared with that of placebo irradiation for the treatment of atopic dermatitis.
We are planning to enroll a total of 150 patients at the University hospitals in Göttingen (Germany), Marburg (Germany), and Geneva (Switzerland).
The trial was approved by the lead ethics committee of the medical faculty of the University of Göttingen (21/11/16). Further approvals were obtained from local and federal authorities (ethics committee Marburg, Cantonal Commission for Research Ethics Geneva, Suisse Medic, and Bundesinstitut für Arzneimittel und Medizinprodukte).
We will disseminate the results in a peer-reviewed journal.
ClinicalTrials.gov NCT03085303; https://clinicaltrials.gov/ct2/show/NCT03085303 (Archived by WebCite at http://www.webcitation.org/73ucqkkA1).
DERR1-10.2196/11911.</description><identifier>ISSN: 1929-0748</identifier><identifier>EISSN: 1929-0748</identifier><identifier>DOI: 10.2196/11911</identifier><identifier>PMID: 30622089</identifier><language>eng</language><publisher>Canada: JMIR Publications</publisher><subject>Chronic illnesses ; Clinical trials ; Dermatitis ; Disease ; Eczema ; Light emitting diodes ; Medical equipment ; Patients ; Protocol ; Psoriasis ; Skin cancer ; Skin diseases ; Substance abuse treatment</subject><ispartof>JMIR research protocols, 2019-01, Vol.8 (1), p.e11911-e11911</ispartof><rights>Christian Kromer, Viktoria P Nühnen, Wolfgang Pfützner, Sebastian Pfeiffer, Hans-Joachim Laubach, Wolf-Henning Boehncke, Joerg Liebmann, Matthias Born, Michael P Schön, Timo Buhl. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 08.01.2019.</rights><rights>2019. This work is licensed under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Christian Kromer, Viktoria P Nühnen, Wolfgang Pfützner, Sebastian Pfeiffer, Hans-Joachim Laubach, Wolf-Henning Boehncke, Joerg Liebmann, Matthias Born, Michael P Schön, Timo Buhl. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 08.01.2019. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c391t-4231637c186c1ab6a01d2b8c638c7c5eb43bc3e7663d58121ee51b4909010dfe3</citedby><cites>FETCH-LOGICAL-c391t-4231637c186c1ab6a01d2b8c638c7c5eb43bc3e7663d58121ee51b4909010dfe3</cites><orcidid>0000-0002-4458-0292 ; 0000-0002-7710-6511 ; 0000-0002-1225-7124 ; 0000-0002-3139-129X ; 0000-0002-6234-2298 ; 0000-0001-9280-2614 ; 0000-0003-2197-4907 ; 0000-0002-6831-6517 ; 0000-0002-0698-4130 ; 0000-0002-8721-724X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329412/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329412/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,27929,27930,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30622089$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kromer, Christian</creatorcontrib><creatorcontrib>Nühnen, Viktoria P</creatorcontrib><creatorcontrib>Pfützner, Wolfgang</creatorcontrib><creatorcontrib>Pfeiffer, Sebastian</creatorcontrib><creatorcontrib>Laubach, Hans-Joachim</creatorcontrib><creatorcontrib>Boehncke, Wolf-Henning</creatorcontrib><creatorcontrib>Liebmann, Joerg</creatorcontrib><creatorcontrib>Born, Matthias</creatorcontrib><creatorcontrib>Schön, Michael P</creatorcontrib><creatorcontrib>Buhl, Timo</creatorcontrib><title>Treatment of Atopic Dermatitis Using a Full-Body Blue Light Device (AD-Blue): Protocol of a Randomized Controlled Trial</title><title>JMIR research protocols</title><addtitle>JMIR Res Protoc</addtitle><description>Irradiation with visible blue light (wavelength 400-495 nm) is a promising, effective, and safe new treatment option for chronic inflammatory skin diseases such as psoriasis and atopic dermatitis.
We will perform a multicenter, placebo-controlled, double-blinded, 3-armed, prospective, randomized controlled trial to investigate the efficacy and safety of full-body blue light devices (wavelengths: 415 nm and 450 nm) compared with that of placebo irradiation for the treatment of atopic dermatitis.
We are planning to enroll a total of 150 patients at the University hospitals in Göttingen (Germany), Marburg (Germany), and Geneva (Switzerland).
The trial was approved by the lead ethics committee of the medical faculty of the University of Göttingen (21/11/16). Further approvals were obtained from local and federal authorities (ethics committee Marburg, Cantonal Commission for Research Ethics Geneva, Suisse Medic, and Bundesinstitut für Arzneimittel und Medizinprodukte).
We will disseminate the results in a peer-reviewed journal.
ClinicalTrials.gov NCT03085303; https://clinicaltrials.gov/ct2/show/NCT03085303 (Archived by WebCite at http://www.webcitation.org/73ucqkkA1).
DERR1-10.2196/11911.</description><subject>Chronic illnesses</subject><subject>Clinical trials</subject><subject>Dermatitis</subject><subject>Disease</subject><subject>Eczema</subject><subject>Light emitting diodes</subject><subject>Medical equipment</subject><subject>Patients</subject><subject>Protocol</subject><subject>Psoriasis</subject><subject>Skin cancer</subject><subject>Skin diseases</subject><subject>Substance abuse treatment</subject><issn>1929-0748</issn><issn>1929-0748</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkdFrFDEQxoMottT7FyQgQn1YzSS72Y0PwvVqVThQ5Pocstm5a0p2cybZSv3rzdlaqvMyw8yPj2_4CFkAe8tByXcACuAJOQbFVcXaunv6aD4ii5SuWamubRWXz8mRYJJz1qlj8nMT0eQRp0zDli5z2DtLzzGOJrvsEr1MbtpRQy9m76uzMNzSMz8jXbvdVS7cjbNIT5fn1WH75j39FkMONviDmKHfzTSE0f3Cga7ClGPwvoyb6Ix_QZ5tjU-4uO8n5PLi42b1uVp__fRltVxXVijIVc0FSNFa6KQF00vDYOB9Z6XobGsb7GvRW4GtlGJoOuCA2EBfK6YYsGGL4oR8uNPdz_2Igy2PRuP1PrrRxFsdjNP_XiZ3pXfhRkvBVQ28CJzeC8TwY8aU9eiSRe_NhGFOmoNsZNO2si7oq__Q6zDHqbynecM6KXmBCvX6jrIxpBRx-2AGmD6kqf-kWbiXj50_UH-zE78BXduXwg</recordid><startdate>20190108</startdate><enddate>20190108</enddate><creator>Kromer, Christian</creator><creator>Nühnen, Viktoria P</creator><creator>Pfützner, Wolfgang</creator><creator>Pfeiffer, Sebastian</creator><creator>Laubach, Hans-Joachim</creator><creator>Boehncke, Wolf-Henning</creator><creator>Liebmann, Joerg</creator><creator>Born, Matthias</creator><creator>Schön, Michael P</creator><creator>Buhl, Timo</creator><general>JMIR Publications</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-4458-0292</orcidid><orcidid>https://orcid.org/0000-0002-7710-6511</orcidid><orcidid>https://orcid.org/0000-0002-1225-7124</orcidid><orcidid>https://orcid.org/0000-0002-3139-129X</orcidid><orcidid>https://orcid.org/0000-0002-6234-2298</orcidid><orcidid>https://orcid.org/0000-0001-9280-2614</orcidid><orcidid>https://orcid.org/0000-0003-2197-4907</orcidid><orcidid>https://orcid.org/0000-0002-6831-6517</orcidid><orcidid>https://orcid.org/0000-0002-0698-4130</orcidid><orcidid>https://orcid.org/0000-0002-8721-724X</orcidid></search><sort><creationdate>20190108</creationdate><title>Treatment of Atopic Dermatitis Using a Full-Body Blue Light Device (AD-Blue): Protocol of a Randomized Controlled Trial</title><author>Kromer, Christian ; Nühnen, Viktoria P ; Pfützner, Wolfgang ; Pfeiffer, Sebastian ; Laubach, Hans-Joachim ; Boehncke, Wolf-Henning ; Liebmann, Joerg ; Born, Matthias ; Schön, Michael P ; Buhl, Timo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c391t-4231637c186c1ab6a01d2b8c638c7c5eb43bc3e7663d58121ee51b4909010dfe3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Chronic illnesses</topic><topic>Clinical trials</topic><topic>Dermatitis</topic><topic>Disease</topic><topic>Eczema</topic><topic>Light emitting diodes</topic><topic>Medical equipment</topic><topic>Patients</topic><topic>Protocol</topic><topic>Psoriasis</topic><topic>Skin cancer</topic><topic>Skin diseases</topic><topic>Substance abuse treatment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kromer, Christian</creatorcontrib><creatorcontrib>Nühnen, Viktoria P</creatorcontrib><creatorcontrib>Pfützner, Wolfgang</creatorcontrib><creatorcontrib>Pfeiffer, Sebastian</creatorcontrib><creatorcontrib>Laubach, Hans-Joachim</creatorcontrib><creatorcontrib>Boehncke, Wolf-Henning</creatorcontrib><creatorcontrib>Liebmann, Joerg</creatorcontrib><creatorcontrib>Born, Matthias</creatorcontrib><creatorcontrib>Schön, Michael P</creatorcontrib><creatorcontrib>Buhl, Timo</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Nursing & Allied Health Premium</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>JMIR research protocols</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kromer, Christian</au><au>Nühnen, Viktoria P</au><au>Pfützner, Wolfgang</au><au>Pfeiffer, Sebastian</au><au>Laubach, Hans-Joachim</au><au>Boehncke, Wolf-Henning</au><au>Liebmann, Joerg</au><au>Born, Matthias</au><au>Schön, Michael P</au><au>Buhl, Timo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of Atopic Dermatitis Using a Full-Body Blue Light Device (AD-Blue): Protocol of a Randomized Controlled Trial</atitle><jtitle>JMIR research protocols</jtitle><addtitle>JMIR Res Protoc</addtitle><date>2019-01-08</date><risdate>2019</risdate><volume>8</volume><issue>1</issue><spage>e11911</spage><epage>e11911</epage><pages>e11911-e11911</pages><issn>1929-0748</issn><eissn>1929-0748</eissn><abstract>Irradiation with visible blue light (wavelength 400-495 nm) is a promising, effective, and safe new treatment option for chronic inflammatory skin diseases such as psoriasis and atopic dermatitis.
We will perform a multicenter, placebo-controlled, double-blinded, 3-armed, prospective, randomized controlled trial to investigate the efficacy and safety of full-body blue light devices (wavelengths: 415 nm and 450 nm) compared with that of placebo irradiation for the treatment of atopic dermatitis.
We are planning to enroll a total of 150 patients at the University hospitals in Göttingen (Germany), Marburg (Germany), and Geneva (Switzerland).
The trial was approved by the lead ethics committee of the medical faculty of the University of Göttingen (21/11/16). Further approvals were obtained from local and federal authorities (ethics committee Marburg, Cantonal Commission for Research Ethics Geneva, Suisse Medic, and Bundesinstitut für Arzneimittel und Medizinprodukte).
We will disseminate the results in a peer-reviewed journal.
ClinicalTrials.gov NCT03085303; https://clinicaltrials.gov/ct2/show/NCT03085303 (Archived by WebCite at http://www.webcitation.org/73ucqkkA1).
DERR1-10.2196/11911.</abstract><cop>Canada</cop><pub>JMIR Publications</pub><pmid>30622089</pmid><doi>10.2196/11911</doi><orcidid>https://orcid.org/0000-0002-4458-0292</orcidid><orcidid>https://orcid.org/0000-0002-7710-6511</orcidid><orcidid>https://orcid.org/0000-0002-1225-7124</orcidid><orcidid>https://orcid.org/0000-0002-3139-129X</orcidid><orcidid>https://orcid.org/0000-0002-6234-2298</orcidid><orcidid>https://orcid.org/0000-0001-9280-2614</orcidid><orcidid>https://orcid.org/0000-0003-2197-4907</orcidid><orcidid>https://orcid.org/0000-0002-6831-6517</orcidid><orcidid>https://orcid.org/0000-0002-0698-4130</orcidid><orcidid>https://orcid.org/0000-0002-8721-724X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1929-0748 |
| ispartof | JMIR research protocols, 2019-01, Vol.8 (1), p.e11911-e11911 |
| issn | 1929-0748 1929-0748 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6329412 |
| source | DOAJ Directory of Open Access Journals; PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Chronic illnesses Clinical trials Dermatitis Disease Eczema Light emitting diodes Medical equipment Patients Protocol Psoriasis Skin cancer Skin diseases Substance abuse treatment |
| title | Treatment of Atopic Dermatitis Using a Full-Body Blue Light Device (AD-Blue): Protocol of a Randomized Controlled Trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T01%3A02%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20Atopic%20Dermatitis%20Using%20a%20Full-Body%20Blue%20Light%20Device%20(AD-Blue):%20Protocol%20of%20a%20Randomized%20Controlled%20Trial&rft.jtitle=JMIR%20research%20protocols&rft.au=Kromer,%20Christian&rft.date=2019-01-08&rft.volume=8&rft.issue=1&rft.spage=e11911&rft.epage=e11911&rft.pages=e11911-e11911&rft.issn=1929-0748&rft.eissn=1929-0748&rft_id=info:doi/10.2196/11911&rft_dat=%3Cproquest_pubme%3E2165657764%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2508662643&rft_id=info:pmid/30622089&rfr_iscdi=true |